Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied

PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 3, 2018

Primary Completion Date

February 14, 2019

Study Completion Date

March 14, 2019

Conditions
Glaucoma, Neovascular
Interventions
DRUG

Aflibercept (EYLEA, BAY86-5321)

2 mg (0.05 mL), Intravitreal injection (IVT), single dose.

DRUG

Topical IOP-lowering drugs

A combination of at least 3 topical IOP-lowering drugs will be administered during a run-in phase before treatment and should be kept unchanged until IOP evaluation at Week 1, after which they may be reduced according to the investigator's opinion

Trial Locations (7)

910-1193

University of Fukui Hospital, Yoshida

671-1227

Tsukazaki Hospital, Himeji

920-8641

Kanazawa University Hospital, Kanazawa

216-8511

St. Marianna University School of Medicine Hospital, Kawasaki

565-0871

Osaka University Hospital, Suita

569-1096

Takatsuki Red Cross Hospital, Takatsuki

693-8501

Shimane University Hospital, Izumo

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY

NCT03639675 - Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied | Biotech Hunter | Biotech Hunter